Strong hospital and ambulatory performance pushed Tenet’s third quarter well ahead of expectations
Tenet Healthcare’s third quarter was driven by two businesses that often move on different rhythms: inpatient hospitals and ambulatory surgery centers. Together, they produced a results package that landed well above Wall Street expectations and gave management enough confidence to raise full-year guidance again. The company reported $5.63 billion in net operating revenues for the quarter, excluding $646 million in contract termination revenue tied to its separation from CommonSpirit Health, and that topline figure exceeded consensus estimates.
The earnings beat was even sharper at the bottom line. Adjusted earnings per share came in at $6.64, far above the prior-year $3.70 and more than 40% ahead of the $4.60 consensus estimate. Adjusted EBITDA reached $1.36 billion, about 16% above estimates cited by Stephens, and the company said the result reflected roughly 10% year-over-year growth once $147 million in one-time items tied to the timing of the CommonSpirit contract winddown were excluded.
Revenue strength came from volume, pricing power, and disciplined expense management
The hospital segment showed a familiar but still important pattern: more activity, modest pricing gains, and a better-than-feared operating mix. Same-hospital admissions rose 2.8% year over year, adjusted admissions increased 3.2%, and hospital surgeries declined 1.1%. Net hospital revenues climbed 6.1% year over year, while revenue per adjusted admission rose just 0.2%. Even with surgical volumes softening, the company said continued pricing strength and volume growth helped offset an 18% decline in exchange admissions and revenues.
A brief sentence captures the quarter’s core tension. Surgical volume was not roaring back.
Even so, hospital adjusted EBITDA advanced from $607 million a year earlier to $818 million, including the one-time items. Supplemental Medicaid payments also contributed more than in the prior year, with a $32 million increase in favorable pre-tax impact and $356 million recognized in total. For a health system operating in an environment of unstable payer mix and uneven procedure growth, those supplemental payments matter because they can soften the strain from commercial-to-government mix shifts and from lower-margin patient populations.
Ambulatory surgery remained the higher-margin engine
Tenet’s ambulatory business again did the heavy lifting on profitability. Same-facility net patient service revenues rose 4.5% year over year even though same-facility cases fell 1.5%. Revenue per case climbed 6.1%, a pattern executives linked to a deliberate strategy of capturing more complex, higher-acuity patients in the outpatient setting. Adjusted EBITDA for the segment increased 9.1% to $537 million.
That combination is central to how the company is positioning itself. Ambulatory surgery centers can absorb a growing share of procedures that once required hospital outpatient departments or inpatient settings, especially as payers and patients continue to pressure the system toward lower-cost sites of care. The business model rewards volume, acuity, and efficiency, not simply raw case counts. A decline in cases can still coexist with better economics if the case mix shifts toward more resource-intensive procedures and reimbursement holds.
Guidance rose again, with management pointing to both fundamentals and one-time items
Based on the quarter, Tenet raised 2026 adjusted EBITDA guidance by $195 million. CEO Saum Sutaria said the increase rests on continued strong fundamental performance as well as one-time items in the second half of the year, and he added that more than 40% of the total guidance increase for 2026 reflects fundamental outperformance rather than temporary effects.
That distinction matters for investors because it separates recurring operating strength from nonrecurring accounting and contract-related tailwinds. A company can post a large guidance bump on the back of settlements, timing shifts, or favorable regulatory timing, but Tenet’s management framed a meaningful share of the improvement as operational. In practical terms, that means hospital admissions, ambulatory pricing, and expense control are doing enough work on their own to justify a better outlook.
Deal activity and share repurchases remain part of the story
The ambulatory market has become increasingly active as health systems and private operators chase growth in lower-cost procedural care. Sutaria addressed two recent large deals — Bon Secours Mercy Health’s planned acquisition of Surgery Partners and Ascension’s close on the AmSurg transaction — and cast Tenet’s platform as the one with differentiated earnings growth. He also pointed to what he described as an attractive valuation for Tenet’s equity relative to reasonable valuations for ASC-hospital combination platforms, which gives the company another rationale to buy back shares.
On the acquisition front, Sutaria said Tenet was successful in securing new ASC acquisitions during the quarter and emphasized that the vast majority were not competitive processes, but opportunities that came directly to the company. In a market where high-quality ambulatory assets are drawing more attention from large health systems, private equity, and strategic buyers, access matters as much as price.
He also framed the sector as one that needs advocacy around quality, safety, and regulatory recognition. Ambulatory surgery centers remain central to the broader push toward lower-cost care delivery, but the consolidation wave will keep scrutiny high on patient selection, procedure complexity, and oversight.
2027 will depend on regulatory clarity and whether current momentum holds
Executives said Tenet is expected to grow overall EBITDA next year after excluding the CommonSpirit contract termination and accounting for the current known regulatory framework, including Medicaid work requirements and supplemental payments. That outlook is encouraging, but it still sits inside a policy environment that can shift quickly. For a company with significant exposure to Medicaid funding mechanics and hospital reimbursement trends, even small changes in supplemental payment rules can alter the earnings trajectory.
One more detail kept the market grounded. Tenet’s stock was trading about 1% below the day’s open early in the afternoon after the report.
The quarter puts Tenet in a better position than several other large for-profit operators, including HCA Healthcare and Universal Health Services, which have flagged payer mix pressure, surgical concerns, and only tepid early guidance for 2027. Tenet’s next test is whether the current balance of hospital volume, ambulatory pricing, and expense discipline can persist without the help of one-time items or unusually favorable reimbursement timing.